

**TENDER NO. BMSIC/DRUGS/18-04**

**Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids**

Company Name <u>      </u> CIPLA <u>      </u> LTD. <u>      </u>		Total Number of Pages Submitted in bid documents <u>      </u> 1 TO 271 <u>      </u>				Remarks
Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	
1	3.(a)	<b>Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft</b> drawn in Favor of “Managing Director, Bihar Medical Services and Infrastructure Corporation Limited” payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	yes	"44"	yes	
2	3.(b)	Bidder are required to submit <b>Earnest Money Deposit in the form of Demand Draft / Bank Guarantee</b> drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/- (Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	yes	"46"	yes	
3	3.(c)	Documentary evidence of the <b>constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed</b> etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	yes	"137" - "114"	yes	
4	3.(d)	The <b>details of Bidder</b> Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	yes	"29"	yes	
5	3.(e)	<b>Power of Attorney or Resolution of Board</b> by which the <b>authorised signatory</b> has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. <b>Format to be used.</b>	yes	"113"	yes	
6	3.(f)	Copies of the <b>Audited Balance Sheet and Profit and Loss statement</b> showing details of their annual average turnover not less than <b>25 Crores</b> for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). <b>Self-attested copies</b> are to be submitted.	yes	"42" & "40" & "38"	yes	

✓

Archana Singh  
14/7/2018

7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	yes	"36"&"35"&"34"	yes	
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	yes	"33"	yes	
9	3.(q)	Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).	yes	"32"	yes	

Archan Singh  
14/7/2018



**TENDER NO. BMSIC/DRUGS/18-04**

**Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids**

**Company name: Cipla Ltd.**

**Total number of pages submitted in bid documents: 271**

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax, Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	29	Yes	-
2	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	Yes	111-113	Yes	-
3		Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.	Yes	199-232, 96-108	Please find the remark	The product of NIT sr. no.-204, have licence in force from 06/01/2016- 31/10/2018
4		Approved product list as per the license issued for quoted drugs for minimum three years.	Yes	199-232, 96-108	No	Licence No. 616 is valid upto 19/05/2018 (NIT sr. no.-42, 105, 106, 137, 138)
5		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	199-232, 96-108	No	Licence No. 616 is valid upto 19/05/2018 License is valid but approved product list is not enclosed with latest renewal certificate
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	-	-	-	-
7	3.(f)	Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	1-25 78-89	No	The Manufacturing and marketing certificate of the products of NIT sr. no.-12 in only for 2012-13, 2013-14, 2014-15, 2015-16 and 2014-15, 2015-2016, 2016-2017 for all the products quoted, except the product of NIT sr. no.-204 for which no document attached in favour of the said drugs sold in India.

8/10/2018  




8		If permission in Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI has been obtained, then the 3 years manufacturing/ Import & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	NO	-	NO	-
9		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCGI (I) shall be required for all new regulated products to this effect.	-	-	-	-
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	-	-	-	-
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	-	-	-	-
11	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	Yes	73-99	No	Importer have only two years old valid licence. Import in India by the bidder firm is from 12/04/2017 to 11/04/2018 and there are no any document attached in favour of the said drug sold in India.
12	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	1-05 1-Jan	No	The product at NIT sr. no.-204, for which there are no document attached in favour of the said drug sold in India.
13	3.(i)	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. Self-attested copies are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	Yes	60-69	Yes	-

8/12/2018



14	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. <b>Self-attested copies</b> are to be submitted.	Yes	54-59	No	For licence No. 611 & 616 this certificate was issued on 05/01/2017 which is older than one year but it is valid upto 15-12-2018.
15	3.(k)	<b>Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. Self-attested copies</b> are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	Yes	50-53	Yes	Maxium Production Capacity for the product at NIT Sr. No. 204 not submitted.
16	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	Yes	48-49	Yes	Whether Blacklisted or not  Not Blacklisted as per the provided Affidavit
17	3.(o)	List of item quoted in prescribed format as per Annexure-III duly signed.	Yes	109-110	Yes	-
18	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	Yes	30-31	Yes	-
19	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	No	-	No	-
20	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	111-113	Yes	-
21	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	-	-	-	-

15/12/2018  
860160181

22	Corrigendum point	A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.	Yes	27	Yes	-
----	-------------------	--	-----	----	-----	---

27/06/2021



## Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: Cipla Ltd.

Total number of pages submitted in bid documents: 271

## Sheet to be used for verification of product approval and market standing

SL No	NIT SL No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	12	Amlodipine Tablets IP	Amlodipine Besilate Tablets IP 2.5 mg Amlpres 2.5	IP/2.5mg	IP/2.5 mg	10 x 10	Not mentioned	Tablet	Tablet	Not mentioned	31/12/2021	Brand	MSC for 13-14, 14-15 and 15-16 submitted in Brand Name
2	13	Amlodipine Tablets IP	Amlodipine Besilate Tablets IP 5 mg Amlpres 5	IP/5mg	IP/5 mg	10 x 10	Not mentioned	Tablet	Tablet	Not mentioned	31/12/2021	Brand	MSC for 14-15, 15-16 and 16-17 submitted in Brand Name
3	22	Artemether+ Lumefantrín	Artemether and Lumefantrín Tablet 80 mg/480 mg	80 mg +480 mg	IP/80 mg+480 mg	10 x 6	Not mentioned	Tablets	Tablets	4/4/2015	4/3/2020	Generic	MSC submitted for 14-15, 15-16 & 16-17 in Brand Name and Pharmacopoeial specification INH
4	24	Azithromycin Tablets IP	Azithromycin Tablets IP 250 mg	IP/250 mg	IP/250 mg	10 x 10	Not mentioned	Tablet	Tablet	4/4/2015	4/3/2020	Generic	MSC submitted for 14-15, 15-16 and 16-17 in Brand Name
5	25	Azithromycin Tablets IP	Azithromycin Tablets IP 500 mg	IP/500 mg	IP/500 mg	10 x 10	Not mentioned	Tablet	Tablet	4/4/2015	4/3/2020	Generic	MSC submitted for 14-15, 15-16 and 16-17 in Brand Name
6	39	Budesonide	Budesonide Nebuliser susp. BP Budecort Respule 0.5 mg	0.5mg/2ml	IP/BP/0.5 mg/2 ml	2ml Ampoule	2ml Respule	Inhalation Suspension	Nebuliser Suspension	Not mentioned	31/12/2021	Brand	MSC for 14-15, 15-16 and 16-17 submitted in Brand Name
7	42	Capecitabine Tablets IP	Capecitabine Tablets IP 500 mg	IP/500 mg	IP/500 mg	10 x 10	10 Tablets in Blister Pack	Tablet	Tablet	22/01/2014	19/05/2018	Generic	MSC submitted for 14-15, 15-16 & 16-17 in Brand Name
8	79	Entecavir Tablet	Entecavir Tablet 0.5 mg	0.5mg	INH/0.5 mg	10x10	Not mentioned	Tablet	Tablet	4/4/2015	4/3/2020	Generic	
9	105	Imatinib Tablet IP	Imatinib Mesylate Tablet IP 100 mg	IP/100mg	IP/100 mg	10x10	10 Tablets in Blister Pack	Tablet	Tablet	22/04/2014	19/05/2018	Generic	
10	106	Imatinib Tablet IP	Imatinib Mesylate Tablet IP 400 mg	IP/400mg	IP/400 mg	10x10	10 Tablets in Blister Pack	Tablet	Tablet	22/04/2014	19/05/2018	Generic	

8/10/2018

27

11	107	Ipratropium Bromide	Ipratropium Nebuliser solution BP Ipratvent Respules	250mcg/ml	IP/500 mcg/2ml	2ml Ampoule	2ml Respule	Nebulizer solution	Nebulizer solution	Not mentioned	31/12/2021	Brand	MSC submitted for 14-15, 15-16 & 16-17 for 250mg/ml
12	122	Levo- salbutamol Tablet	Levosaltamol Tablet 2 mg Livolin -2	2mg	IP/2mg	10x10	Not mentioned	Tablet	Tablet	Not mentioned	31/12/2021	Brand	MSC submitted for 14-15, 15-16 & 16-17
13	126	Linezolid IP	Linezolid Tablets IP 600 mg Linospan 600	IP/600mg	IP/600 mg	10x10	Not mentioned	Tablet	Tablet	Not mentioned	31/12/2021	Brand	MSC submitted for 14-15, 15-16 & 16-17
14	137	Methotrexate Tablet	Methotrexate Tablet IP 2.5 mg	IP/2.5mg	IP/2.5 mg	10x10	10 Tablets in Blister Pack	Tablet	Tablet	30/12/2013	19/05/2018	Generic	MSC submitted for 14-15, 15-16 & 16-17 in Brand Name
15	138	Methotrexate Tablet	Methotrexate Tablet IP 7.5 mg	7.5 mg	IP/7.5 mg	10x10	Not mentioned	Tablet	Tablet	27/12/2013	19/05/2018	Generic	
16	155	Misoprostol Tablets IP	Misoprostol Tablets 200 mcg Misoprost 200	IP/200µg	200 mcg	10x10's	04 Tablets in Blister Pack	Tablets	Tablets	18/02/2005	18/03/2023	Brand	MSC submitted for 14-15, 15-16 & 16-17
17	190	Ramipril Tablet IP	Ramipril Tablet IP 2.5 mg	IP/2.5mg	IP/2.5 mg	10x10	Not mentioned	Tablet	Tablet	4/4/2015	4/3/2020	Generic	MSC submitted for 14-15, 15-16 & 16-17 in Brand Name
18	191	Ramipril Tablet IP	Ramipril Tablet IP 5mg	IP/5mg	IP/5 mg	10x10	Not mentioned	Tablet	Tablet	4/4/2015	4/3/2020	Generic	
19	204	Surfactant	Bovine Lipid extract surfactant Suspension (Neosurf)	Per mg of Phospholipids in the pack	Per ml	-----	3 ml vials 5 ml vials	Suspension for Intratracheal Instillation (As licensed)	Suspension	1/6/2016	31/10/2018	Brand	MSC Related to Sell in India not submitted
20	215	Telmisartan Tablet IP	Telmisartan Tablet IP 20 mg Cresar-20	IP/20mg	IP/20mg	10x10	Not mentioned	Tablet	Tablet	Not mentioned	31/12/2021	Brand	MSC submitted for 14-15, 15-16 & 16-17

8/10/2018



TENDER NO. BMSIC/DRUGS/18-04												
Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids												
Company name: Cipla Ltd.												
Total number of pages submitted in bid documents: 271												
Sheet for verification of licence details												
Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)		To	From
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To				
1	12	Amlodipine Tablets IP	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2019		
2	13	Amlodipine Tablets IP	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2019		
3	22	Artemether+ Lumefantrin	25	109	—	—	4/4/2005	03-04-2020	12/28/2017	12/27/2019		
4	24	Azithromycin Tablets IP	28	110	—	—	4/4/2005	03-04-2020	12/28/2017	12/27/2019		
5	25	Azithromycin Tablets IP	28	110	—	—	4/4/2005	03-04-2020	12/28/2017	12/27/2019		
6	39	Budesonide	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2019		
7	42	Capecitabine Tablets IP	25	616	—	—	20/05/2003	19-05-2018	1/5/2017	12/15/2018		
8	79	Entecavir Tablet	25	109	—	—	4/4/2005	03-04-2020	12/28/2017	12/27/2019		
9	105	Imatinib Tablet IP	25	616	—	—	20/05/2003	19-05-2018	1/5/2017	12/15/2018		
10	106	Imatinib Tablet IP	25	616	—	—	20/05/2003	19-05-2018	1/5/2017	12/15/2018		
11	107	Iprratriptium Bromide	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2019		

8/10/2018

12	122	Levo- salbutamol Tablet	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2017
13	126	Linezolid IP	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2019
14	137	Methotrexate Tablet	25	616	—	—	20/05/2003	19-05-2018	1/5/2017	12/15/2018
15	138	Methotrexate Tablet	25	616	—	—	20/05/2003	19-05-2018	1/5/2017	12/15/2018
16	155	Misoprostol Tablets IP	28	611	—	—	19/03/2003	18-03-2023	1/5/2017	12/15/2018
17	190	Ramipril Tablet IP	25	109	—	—	4/4/2005	03-04-2020	12/28/2017	12/27/2019
18	191	Ramipril Tablet IP	25	109	—	—	4/4/2005	03-04-2020	12/28/2017	12/27/2019
19	204	Surfactant	—	—	10	FF-532-31576	1/6/2016	31-10-2018	8/25/2017	8/24/2018
20	215	Telmisartan Tablet IP	25	447	—	—	21/03/2007	31-12-2021	9/25/2017	9/22/2019

**Note:-** Assisted in technical evaluation in reference to letter No-559(15), dated 26.6.2018 on the basis of documents provided by BMSICL in checklist-II, III & IV. Provided checklist compiled with due diligence and care. Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time, if any discrepancies are observed, for rectification.

*Shobha Bhat*